Shots:
- The EC has approved Poherdy (420mg/14mL, IV), an interchangeable biosimilar version of Perjeta (pertuzumab) for all indications of the reference product
- Approval was based on extensive data, incl. structural & functional analytical data, PK & clinical studies, which showed similarity & interchangeability in terms of analytical, PK, efficacy, safety, & immunogenicity between Poherdy & reference pertuzumab
- In 2022, Henlius granted Organon exclusive global commercialization rights for multiple biosimilars, incl. Poherdy, under a license & supply agreement, covering all regions except for China
Ref: PRnewswire | Image: Henlius & Organon | Press Release
Related News: Henlius Receives NMPA IND Clearance for HLX05-N (Biosimilar, Erbitux)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
